Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- UCB Japan Seeks Lennox-Gastaut Syndrome Indication for Fintepla
June 28, 2023
- Chugai to Form Corporate VC in Boston to Drive Innovation
June 28, 2023
- UBE, IPSC Startup Grab US Orphan Tag for IPF Therapy
June 28, 2023
- Rexulti Makes Mark in Japan PIII Study for Alzheimer’s Agitation: Otsuka
June 28, 2023
- Merck Biopharma, Pfizer Japan to End Bavencio Copromotion
June 28, 2023
- Amgen Japan to Cut 30 Jobs in Evenity Sales Unit as It Rejigs Organization
June 27, 2023
- Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
- Lonsurf-Bevacizumab Combo Nabs EU Panel Nod for Colorectal Cancer
June 27, 2023
- Shionogi Snaps Up Qpex to Boost Antimicrobial Pipeline
June 27, 2023
- Zenyaku Kogyo Bags Japan Rights to Singapore Firm’s Eczema Med
June 26, 2023
- Veritas, Takeda Link Up for mRNA-Targeted Drug Discovery against Genetic Disorders
June 26, 2023
- Japan Pharma Market Projected to Grow 0.5-1.5% through FY2027: IQVIA
June 26, 2023
- Nobelpharma Grants Authorized Generic Rights to Japanese Firm
June 26, 2023
- Shionogi CEO Hauls In 292 Million Yen after Record Year
June 26, 2023
- Kris Sisneros Takes Helm at LEO Pharma Japan
June 23, 2023
- Gilead Completes Marketing Authorization Transfer for Yescarta in Japan
June 23, 2023
- Astellas Chairman Snags 452 Million Yen in FY2022: Securities Report
June 23, 2023
- Combined Sales of 26 Japan Drug Makers Up 13.6% in FY2022 on Global Growth, COVID Demand
June 22, 2023
- Nippon Shinyaku Files Jazz’s High-Risk AML Drug in Japan
June 22, 2023
- 4 Eisai Execs Earn 100 Million Yen-Plus Pay, CEO Takes Home 157 Million Yen
June 22, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…